These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 29733389)

  • 1. Temozolomide for immunomodulation in the treatment of glioblastoma.
    Karachi A; Dastmalchi F; Mitchell DA; Rahman M
    Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
    Gholamin S; Youssef OA; Rafat M; Esparza R; Kahn S; Shahin M; Giaccia AJ; Graves EE; Weissman I; Mitra S; Cheshier SH
    Innate Immun; 2020 Feb; 26(2):130-137. PubMed ID: 31547758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
    Antonopoulos M; VAN Gool SW; Dionysiou D; Graf N; Stamatakos G
    Anticancer Res; 2019 Apr; 39(4):2043-2051. PubMed ID: 30952748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
    Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T
    Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
    Chua J; Nafziger E; Leung D
    Curr Oncol Rep; 2019 Mar; 21(4):30. PubMed ID: 30835007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes.
    Jezierzański M; Nafalska N; Stopyra M; Furgoł T; Miciak M; Kabut J; Gisterek-Grocholska I
    Curr Oncol; 2024 Jul; 31(7):3994-4002. PubMed ID: 39057168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
    Voce DJ; Bernal GM; Wu L; Crawley CD; Zhang W; Mansour NM; Cahill KE; Szymura SJ; Uppal A; Raleigh DR; Spretz R; Nunez L; Larsen G; Khodarev NN; Weichselbaum RR; Yamini B
    Cancer Res; 2019 May; 79(10):2536-2548. PubMed ID: 30940658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
    Lee IY; Hanft S; Schulder M; Judy KD; Wong ET; Elder JB; Evans LT; Zuccarello M; Wu J; Aulakh S; Agarwal V; Ramakrishna R; Gill BJ; Quiñones-Hinojosa A; Brennan C; Zacharia BE; Silva Correia CE; Diwanji M; Pennock GK; Scott C; Perez-Olle R; Andrews DW; Boockvar JA
    Future Oncol; 2024 Mar; 20(10):579-591. PubMed ID: 38060340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice.
    Salma S; Djan I; Bjelan M; Vulekovic P; Novakovic M; Vidovic V; Lucic M
    J BUON; 2017; 22(5):1233-1239. PubMed ID: 29135107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex as a biological variable in response to temozolomide.
    Russell L; Bolyard C; Banasavadi-Siddegowda Y; Weiss A; Zhang J; Shakya R; Powell K; Kaur B
    Neuro Oncol; 2017 Jun; 19(6):873-874. PubMed ID: 28379437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.